Methylxanthines: Potential Therapeutic Agents for Glioblastoma

• Hauptverfasser: Daniel Pérez-Pérez (Verfasst von), Iannel Reyes-Vidal (Verfasst von), Elda Georgina Chávez-Cortez (Verfasst von), Julio Sotelo (Verfasst von), Roxana Magaña-Maldonado (Verfasst von)
• Format: Buch
• Veröffentlicht: MDPI AG, 2019-09-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Currently, treatment is ineffective and the median overall survival is 20.9 months. The poor prognosis of GBM is a consequence of several altered signaling pathways that favor the proliferation and survival of neoplastic cells...